Cytokine replacement in patients with HIV-1 non-Hodgkin's lymphoma: The rationale for low-dose interleukin-2 therapy

Manisha H. Shah, Robert A. Baiocchi, Todd A. Fehniger, Vijay P. Khatri, Margaret Gould, Bernard Poiesz, Zale P. Bernstein, Michael A. Caligiuri

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

PURPOSE. The drastic increase in the incidence of non-Hodgkin's lymphoma in patients infected with HIV-1 is testimony to the fact that our immune system is critical for the prevention of certain malignancies. Preclinical and clinical studies were conducted to (1) gain further insight into defects in immunity that can lead to malignant transformation and (2) determine if certain immune deficiencies could be corrected by cytokines delivered at doses that result in near-physiologic concentrations in vivo. METHODS. We have used the severe combined immune deficient mouse engrafted with human peripheral blood leukocytes from healthy individuals who are seropositive for the Epstein-Barr virus to study the spontaneous development of malignant Epstein-Barr virus-positive human B-cell lymphoproliferative disorder. RESULTS. We have demonstrated in this model that, in the absence of CD4+ T cells, cytokine replacement with low-dose interleukin (IL)-2 therapy can prevent Epstein-Barr virus-positive human B-cell lymphoproliferative disorder by interacting with mouse natural killer and human CD8+ T cells. We review our clinical experience with administration of low-dose IL-2 therapy in patients with HIV-1-related cancer, noting minimal toxicity and significant immune modulation. We provide evidence that this therapy can favorably alter the type 1 cytokine profile in vivo in these patients, and improve the cellular response to infectious insults in vitro. CONCLUSION. Early clinical studies with low-dose IL-2 therapy in patents with HIV-1-related lymphoma suggest that this therapy may have a role in the prevention and treatment of this disease.

Original languageEnglish (US)
JournalCancer Journal from Scientific American
Volume6
Issue numberSUPPL. 1
StatePublished - Feb 2000
Externally publishedYes

Fingerprint

Non-Hodgkin's Lymphoma
Interleukin-2
HIV-1
Cytokines
Human Herpesvirus 4
Lymphoproliferative Disorders
B-Lymphocytes
Therapeutics
AIDS-Related Lymphoma
T-Lymphocytes
Patents
Immune System
Immunity
Neoplasms
Leukocytes
Incidence
Clinical Studies

Keywords

  • Cytokine therapy
  • HIV-1
  • Interleukin-2
  • Non-Hodgkin's lymphoma
  • Translational research

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Shah, M. H., Baiocchi, R. A., Fehniger, T. A., Khatri, V. P., Gould, M., Poiesz, B., ... Caligiuri, M. A. (2000). Cytokine replacement in patients with HIV-1 non-Hodgkin's lymphoma: The rationale for low-dose interleukin-2 therapy. Cancer Journal from Scientific American, 6(SUPPL. 1).

Cytokine replacement in patients with HIV-1 non-Hodgkin's lymphoma : The rationale for low-dose interleukin-2 therapy. / Shah, Manisha H.; Baiocchi, Robert A.; Fehniger, Todd A.; Khatri, Vijay P.; Gould, Margaret; Poiesz, Bernard; Bernstein, Zale P.; Caligiuri, Michael A.

In: Cancer Journal from Scientific American, Vol. 6, No. SUPPL. 1, 02.2000.

Research output: Contribution to journalArticle

Shah, MH, Baiocchi, RA, Fehniger, TA, Khatri, VP, Gould, M, Poiesz, B, Bernstein, ZP & Caligiuri, MA 2000, 'Cytokine replacement in patients with HIV-1 non-Hodgkin's lymphoma: The rationale for low-dose interleukin-2 therapy', Cancer Journal from Scientific American, vol. 6, no. SUPPL. 1.
Shah, Manisha H. ; Baiocchi, Robert A. ; Fehniger, Todd A. ; Khatri, Vijay P. ; Gould, Margaret ; Poiesz, Bernard ; Bernstein, Zale P. ; Caligiuri, Michael A. / Cytokine replacement in patients with HIV-1 non-Hodgkin's lymphoma : The rationale for low-dose interleukin-2 therapy. In: Cancer Journal from Scientific American. 2000 ; Vol. 6, No. SUPPL. 1.
@article{b01b043f7cde45afbdbd359f036b4055,
title = "Cytokine replacement in patients with HIV-1 non-Hodgkin's lymphoma: The rationale for low-dose interleukin-2 therapy",
abstract = "PURPOSE. The drastic increase in the incidence of non-Hodgkin's lymphoma in patients infected with HIV-1 is testimony to the fact that our immune system is critical for the prevention of certain malignancies. Preclinical and clinical studies were conducted to (1) gain further insight into defects in immunity that can lead to malignant transformation and (2) determine if certain immune deficiencies could be corrected by cytokines delivered at doses that result in near-physiologic concentrations in vivo. METHODS. We have used the severe combined immune deficient mouse engrafted with human peripheral blood leukocytes from healthy individuals who are seropositive for the Epstein-Barr virus to study the spontaneous development of malignant Epstein-Barr virus-positive human B-cell lymphoproliferative disorder. RESULTS. We have demonstrated in this model that, in the absence of CD4+ T cells, cytokine replacement with low-dose interleukin (IL)-2 therapy can prevent Epstein-Barr virus-positive human B-cell lymphoproliferative disorder by interacting with mouse natural killer and human CD8+ T cells. We review our clinical experience with administration of low-dose IL-2 therapy in patients with HIV-1-related cancer, noting minimal toxicity and significant immune modulation. We provide evidence that this therapy can favorably alter the type 1 cytokine profile in vivo in these patients, and improve the cellular response to infectious insults in vitro. CONCLUSION. Early clinical studies with low-dose IL-2 therapy in patents with HIV-1-related lymphoma suggest that this therapy may have a role in the prevention and treatment of this disease.",
keywords = "Cytokine therapy, HIV-1, Interleukin-2, Non-Hodgkin's lymphoma, Translational research",
author = "Shah, {Manisha H.} and Baiocchi, {Robert A.} and Fehniger, {Todd A.} and Khatri, {Vijay P.} and Margaret Gould and Bernard Poiesz and Bernstein, {Zale P.} and Caligiuri, {Michael A.}",
year = "2000",
month = "2",
language = "English (US)",
volume = "6",
journal = "Cancer journal (Sudbury, Mass.)",
issn = "1528-9117",
publisher = "Lippincott Williams and Wilkins",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Cytokine replacement in patients with HIV-1 non-Hodgkin's lymphoma

T2 - The rationale for low-dose interleukin-2 therapy

AU - Shah, Manisha H.

AU - Baiocchi, Robert A.

AU - Fehniger, Todd A.

AU - Khatri, Vijay P.

AU - Gould, Margaret

AU - Poiesz, Bernard

AU - Bernstein, Zale P.

AU - Caligiuri, Michael A.

PY - 2000/2

Y1 - 2000/2

N2 - PURPOSE. The drastic increase in the incidence of non-Hodgkin's lymphoma in patients infected with HIV-1 is testimony to the fact that our immune system is critical for the prevention of certain malignancies. Preclinical and clinical studies were conducted to (1) gain further insight into defects in immunity that can lead to malignant transformation and (2) determine if certain immune deficiencies could be corrected by cytokines delivered at doses that result in near-physiologic concentrations in vivo. METHODS. We have used the severe combined immune deficient mouse engrafted with human peripheral blood leukocytes from healthy individuals who are seropositive for the Epstein-Barr virus to study the spontaneous development of malignant Epstein-Barr virus-positive human B-cell lymphoproliferative disorder. RESULTS. We have demonstrated in this model that, in the absence of CD4+ T cells, cytokine replacement with low-dose interleukin (IL)-2 therapy can prevent Epstein-Barr virus-positive human B-cell lymphoproliferative disorder by interacting with mouse natural killer and human CD8+ T cells. We review our clinical experience with administration of low-dose IL-2 therapy in patients with HIV-1-related cancer, noting minimal toxicity and significant immune modulation. We provide evidence that this therapy can favorably alter the type 1 cytokine profile in vivo in these patients, and improve the cellular response to infectious insults in vitro. CONCLUSION. Early clinical studies with low-dose IL-2 therapy in patents with HIV-1-related lymphoma suggest that this therapy may have a role in the prevention and treatment of this disease.

AB - PURPOSE. The drastic increase in the incidence of non-Hodgkin's lymphoma in patients infected with HIV-1 is testimony to the fact that our immune system is critical for the prevention of certain malignancies. Preclinical and clinical studies were conducted to (1) gain further insight into defects in immunity that can lead to malignant transformation and (2) determine if certain immune deficiencies could be corrected by cytokines delivered at doses that result in near-physiologic concentrations in vivo. METHODS. We have used the severe combined immune deficient mouse engrafted with human peripheral blood leukocytes from healthy individuals who are seropositive for the Epstein-Barr virus to study the spontaneous development of malignant Epstein-Barr virus-positive human B-cell lymphoproliferative disorder. RESULTS. We have demonstrated in this model that, in the absence of CD4+ T cells, cytokine replacement with low-dose interleukin (IL)-2 therapy can prevent Epstein-Barr virus-positive human B-cell lymphoproliferative disorder by interacting with mouse natural killer and human CD8+ T cells. We review our clinical experience with administration of low-dose IL-2 therapy in patients with HIV-1-related cancer, noting minimal toxicity and significant immune modulation. We provide evidence that this therapy can favorably alter the type 1 cytokine profile in vivo in these patients, and improve the cellular response to infectious insults in vitro. CONCLUSION. Early clinical studies with low-dose IL-2 therapy in patents with HIV-1-related lymphoma suggest that this therapy may have a role in the prevention and treatment of this disease.

KW - Cytokine therapy

KW - HIV-1

KW - Interleukin-2

KW - Non-Hodgkin's lymphoma

KW - Translational research

UR - http://www.scopus.com/inward/record.url?scp=0033848577&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033848577&partnerID=8YFLogxK

M3 - Article

C2 - 10685658

AN - SCOPUS:0033848577

VL - 6

JO - Cancer journal (Sudbury, Mass.)

JF - Cancer journal (Sudbury, Mass.)

SN - 1528-9117

IS - SUPPL. 1

ER -